Skip to main content
Premium Trial:

Request an Annual Quote

Mitomics Inks Sales and Marketing Deal with LabCorp

NEW YORK (GenomeWeb News) – Mitomics today announced a deal with Laboratory Corporation of America to offer Mitomics' molecular prostate cancer test.

Under the terms of the deal, urologists will be able to order Mitomics' Prostate Core Mitomic Test through Dianon Systems, LabCorp's specialized laboratory subsidiary focused on anatomic pathology. The test will be performed at Mitomics' CLIA laboratory in Aurora, Colo.

"This agreement supports our commercial strategy to provide broad access to [the test] and further validates the strong demand from physicians to improve the diagnosis of prostate cancer for patients," Robert Poulter, president and CEO of Thunder Bay, Ontario-based Mitomics, said in a statement.

The mitochondrial DNA-based test uses previously obtained prostate biopsy tissue to determine the presence of malignant cells "via a cancerization field effect" by detecting molecular changes in tissue that appears normal.

Financial terms of the deal were not disclosed.

Mitomics last month announced a realignment of its product development operations, resulting in the elimination of eight jobs. Earlier in the year, it signed a non-exclusive deal with LabMD to market the Prostate Core Mitomic Test in the US.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.